PLK3 and neoplasm: This report provides the first evidence that ALDH1A1 and PLK3 could potentially serve as prognostic biomarkers for patients with PCa treated with radiotherapy and potential targets to eliminate metastasis-initiating and radioresistant tumor cell populations.